Thus, they assessed the expression level of fatty acid synthase (FASN) and their function in a preclinical model of HER2+ GC and evaluated the inhibition of FASN impacting on resistance to anti-HER2 treatment in HER2+ GC, especially when targeting HER2+ cancer stem cells (CSCs). This evidence concerns the gene ERBB2 and gastric cancer.